论文部分内容阅读
目的探讨帕金森病(Parkinson’s disease,PD)患者伴发高同型半胱氨酸血症(hyperhomocysteinemia,Hhcy)与左旋多巴(levodopa,L-dopa)治疗的关系。方法收集门诊154例PD患者,检测其同型半胱氨酸(Homocysteine,Hcy)的水平。高于正常值者列为研究组,正常值范围内为对照组,2组就年龄、性别、病程、L-dopa治疗情况、叶酸和维生素B12水平等进行对照分析。结果研究组使用L-dopa治疗者比例(62/76))明显高于对照组(44/78)(P<0.01),而其他因素包括性别、年龄、病程、叶酸和维生素B12浓度对Hcy的升高而无明显影响(P>0.05);治疗组血浆Hcy浓度(24.34±8.67)umol/L明显高于未治疗组(14.26±6.11)umol/L(P<0.01)。结论L-dopa治疗可以导致PD患者的血浆Hcy水平升高,可能是PD患者伴发Hhcy的独立危险因素。
Objective To investigate the relationship between hyperhomocysteinemia (Hhcy) and levodopa (L-dopa) in patients with Parkinson’s disease (PD). Methods A total of 154 patients with PD were collected and their homocysteine (Hcy) levels were measured. Those who were higher than normal were included in the study group and those in the normal range were the control group. The two groups were compared on age, sex, course of disease, L-dopa treatment, folic acid and vitamin B12 levels. Results The proportion of patients treated with L-dopa (62/76) in the study group was significantly higher than that in the control group (44/78) (P <0.01). Other factors included gender, age, course of disease, folic acid and vitamin B12 (24.34 ± 8.67) umol / L in the treatment group was significantly higher than that in the untreated group (14.26 ± 6.11) umol / L (P <0.01). Conclusions L-dopa treatment can lead to an increase of plasma Hcy levels in PD patients, which may be an independent risk factor for Hcy in patients with PD.